Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 6097 - 6104 of 12143 results

Insincere Licensing Discussions Can Support a Willful Infringement Claim

June 4, 2018| Blog| Viewpoint

A Rundown of Recent State Action Relating to Medicaid Expansion

June 4, 2018| Blog| Viewpoint

ML Strategies Health Care Preview - June 4, 2018

June 4, 2018| Blog| Viewpoint

Is SEP Licensing Up To Standard?

June 4, 2018| News

Supreme Court Rules on Class Action Waivers in Arbitration Agreements

June 1, 2018| News

5Pointz and the Visual Artists Rights Act of 1990

June 1, 2018| Blog| Viewpoint

White Collar, Regulatory & Compliance Trailblazers

May 31, 2018| News

Smartphone Wars – The Last Jury: Samsung Owes $539M for Infringing Apple’s Patents

May 31, 2018| Blog| Viewpoint

News & Press Releases

Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash

September 16, 2025

Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.

Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber

September 15, 2025

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

View all News and Press Releases